Cancers & treatments·Regimen libraryFirst line

Osimertinib

Checked 2026-09-09

EGFR ex19del or L858R NSCLC: first line metastatic (FLAURA), adjuvant for 3 years after resection (ADAURA), after chemoradiation (LAURA)

One cycle

every 28 days

28-day cycle, until progression; 3 years adjuvantOral Daily oral course

Components

Drug	Dose	Route	Days	Note
Osimertinib Small-molecule kinase inhibitor (EGFR)	80 mg once daily	Oral	D1-28

Cycles

until progression; 3 years adjuvant

28-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Notes

FLAURA2 adds pemetrexed-platinum × 4 then pemetrexed maintenance for a PFS gain at the cost of chemotherapy toxicity.
QTc and LVEF monitoring; strong CYP3A inducers reduce exposure.

Used in

Non-small-cell lung cancer

Trials

FLAURA2 ADAURA LAURA

Products

Osimertinib

Source

FLAURA, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.